StartsidePRE • NASDAQ
add
Prenetics Global Ltd
Forrige sluttkurs
4,50 $
Dagsintervall
4,43 $ - 4,43 $
Årsintervall
2,85 $ - 7,84 $
Markedsverdi
53,16 mill. USD
Gjennomsnittlig volum
6,93k
P/E-tall
-
Utbytte
-
Hovedbørs
NASDAQ
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
(USD) | juni 2024info | Endring år til år |
---|---|---|
Omsetning | 5,94 mill. | 4,32 % |
Driftskostnader | 14,38 mill. | 0,52 % |
Nettoomsetning | −10,72 mill. | 50,83 % |
Netto resultatmargin | −180,46 | 52,87 % |
Fortjeneste per aksje | — | — |
EBITDA | −9,51 mill. | 13,59 % |
Faktisk avgiftssats | 0,79 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
(USD) | juni 2024info | Endring år til år |
---|---|---|
Kontant / kortsiktige inv. | 63,89 mill. | −67,46 % |
Totale aktiva | 233,31 mill. | −16,93 % |
Totale passiva | 42,30 mill. | −30,22 % |
Total egenkapital | 191,00 mill. | — |
Utestående aksjer | 12,22 mill. | — |
P/B-forhold | 0,29 | — |
Avkastning på aktiva | −11,12 % | — |
Avkastning på kapital | −13,33 % | — |
Kontantstrøm
Netto kontantstrøm
(USD) | juni 2024info | Endring år til år |
---|---|---|
Nettoomsetning | −10,72 mill. | 50,83 % |
Kontantstrøm fra drift | — | — |
Kontanter fra investering | — | — |
Kontanter fra finansiering | — | — |
Netto kontantstrøm | — | — |
Fri kontantstrøm | — | — |
Om
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Grunnlagt
2014
Nettsted
Ansatte
322